Denise Carter - Quoin Pharmaceuticals COO CoFounder
| QNRX Stock | USD 0.60 0.01 1.69% |
Insider
Denise Carter is COO CoFounder of Quoin Pharmaceuticals Ltd
| Age | 55 |
| Address | 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349 |
| Phone | 703 980 4182 |
| Web | https://quoinpharma.com |
Denise Carter Latest Insider Activity
Tracking and analyzing the buying and selling activities of Denise Carter against Quoin Pharmaceuticals stock is an integral part of due diligence when investing in Quoin Pharmaceuticals. Denise Carter insider activity provides valuable insight into whether Quoin Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Quoin Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quoin Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Denise Carter over a year ago Acquisition by Denise Carter of 80966 shares of Quoin Pharmaceuticals subject to Rule 16b-3 |
Quoin Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3632) % which means that it has lost $0.3632 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0003) %, meaning that it created substantial loss on money invested by shareholders. Quoin Pharmaceuticals' management efficiency ratios could be used to measure how well Quoin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.71 in 2024. Return On Capital Employed is likely to drop to -1.15 in 2024. At this time, Quoin Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.1 M in 2024, whereas Total Assets are likely to drop slightly above 11.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan MS | Eliem Therapeutics | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Anne Moon | Tempest Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| James JD | Eliem Therapeutics | 58 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Carl Langren | Lumos Pharma | 69 | |
| MD BA | Lumos Pharma | 69 | |
Management Performance
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.36 |
Quoin Pharmaceuticals Management Team
Elected by the shareholders, the Quoin Pharmaceuticals' board of directors comprises two types of representatives: Quoin Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quoin. The board's role is to monitor Quoin Pharmaceuticals' management team and ensure that shareholders' interests are well served. Quoin Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quoin Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Myers, CEO CoFounder | ||
| Gordon JD, Chief Officer | ||
| Denise Carter, COO CoFounder |
Quoin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quoin Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | (7.28 M) | ||||
| Shares Outstanding | 5.05 M | ||||
| Shares Owned By Insiders | 2.44 % | ||||
| Shares Owned By Institutions | 5.88 % | ||||
| Number Of Shares Shorted | 274.49 K | ||||
| Price To Book | 0.56 X | ||||
| EBITDA | (9.27 M) | ||||
| Net Income | (8.69 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.